SELLAS Life Sciences Group, Inc. (SLS)
11.54
+0.19
(+1.67%)
USD |
NASDAQ |
Oct 23, 16:00
11.59
+0.05
(+0.43%)
Pre-Market: 20:00
SELLAS Life Sciences Group Enterprise Value : 2.192B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 2.192B |
| October 22, 2026 | 2.154B |
| October 21, 2026 | 2.314B |
| October 20, 2026 | 2.281B |
| October 19, 2026 | 1.980B |
| October 16, 2026 | 1.877B |
| October 15, 2026 | 2.152B |
| October 14, 2026 | 2.261B |
| October 13, 2026 | 2.368B |
| October 12, 2026 | 2.271B |
| October 09, 2026 | 2.215B |
| October 08, 2026 | 2.136B |
| October 07, 2026 | 2.146B |
| October 06, 2026 | 2.152B |
| October 05, 2026 | 2.211B |
| October 02, 2026 | 2.233B |
| October 01, 2026 | 2.150B |
| September 30, 2026 | 2.348B |
| September 29, 2026 | 2.186B |
| September 28, 2026 | 2.203B |
| September 25, 2026 | 2.207B |
| September 24, 2026 | 2.281B |
| September 23, 2026 | 2.188B |
| September 22, 2026 | 2.289B |
| September 21, 2026 | 2.158B |
| Date | Value |
|---|---|
| September 18, 2026 | 2.182B |
| September 17, 2026 | 2.190B |
| September 16, 2026 | 2.217B |
| September 15, 2026 | 2.142B |
| September 14, 2026 | 2.230B |
| September 11, 2026 | 2.193B |
| September 10, 2026 | 2.586B |
| September 09, 2026 | 2.679B |
| September 08, 2026 | 2.681B |
| September 04, 2026 | 2.661B |
| September 03, 2026 | 2.629B |
| September 02, 2026 | 2.721B |
| September 01, 2026 | 2.532B |
| August 31, 2026 | 2.556B |
| August 28, 2026 | 2.530B |
| August 27, 2026 | 2.933B |
| August 26, 2026 | 2.635B |
| August 25, 2026 | 2.707B |
| August 24, 2026 | 2.755B |
| August 21, 2026 | 2.984B |
| August 20, 2026 | 2.568B |
| August 19, 2026 | 2.659B |
| August 18, 2026 | 2.507B |
| August 17, 2026 | 2.487B |
| August 14, 2026 | 2.443B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 569.05B |
| ImmunityBio, Inc. | 9.529B |
| TG Therapeutics, Inc. | 8.494B |
| Capricor Therapeutics, Inc. | 197.70M |
| Relay Therapeutics, Inc. | 3.093B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.605M |
| Total Expenses (Quarterly) | 9.605M |
| EPS Diluted (Quarterly) | -0.0508 |
| Earnings Yield | -1.84% |
| Normalized Earnings Yield | -1.839 |